Is Epigral a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Epigral Ltd is a good quality company .

Is Epigral undervalued or overvalued?

The key valuation ratios of Epigral Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Epigral share price return in the past 10 years?

Data is not available for this company

Is Epigral a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Epigral Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

Epigral Ltd - Stock Valuation and Financial Performance

Name: Epigral
Brand: Epigral

BSE: 543332 | NSE: EPIGRAL | Chemicals | Small Cap

Place order

Epigral Share Price

₹1,976 -91.20 -4.41%
as on 18-Nov'24 16:59

10 Year X-Ray of Epigral:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	13.8%	22.3%	18.5%	37.9%	36.9%	15.9%	16.7%	29.4%	32.2%	17.7%	-
Value Creation Index ⓘ	0.0	0.7	0.4	1.8	1.7	0.2	0.2	1.1	1.3	0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	352	398	392	598	710	611	829	1,551	2,188	1,929	2,273
Sales YoY Gr.	-	13.2%	-1.7%	52.6%	18.9%	-14.1%	35.7%	87.2%	41.1%	-11.8%	-
Adj EPS ⓘ	4.8	9.5	9.3	22	43.5	26.7	24	60.4	84.1	45.7	67.8
YoY Gr.	-	96.9%	-1.4%	135.2%	97.8%	-38.5%	-10.1%	151.3%	39.4%	-45.8%	-
BVPS (₹) ⓘ	30.6	41.7	51.1	73.1	68.4	89.7	113.9	174.7	257.3	301.8	401.6
Adj Net Profit ⓘ	34	67	66.1	155	179	111	99.8	251	350	190	293
Cash Flow from Ops. ⓘ	113	123	138	225	261	165	229	284	626	398	-
Debt/CF from Ops. ⓘ	2.3	1.5	0.9	0.3	1.5	3.2	2.4	3.5	1.4	2.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	20.8%	22.1%	32.5%	-11.8%
Adj EPS ⓘ	28.4%	1%	23.9%	-45.8%
BVPSⓘ	29%	34.6%	38.4%	17.3%
Share Price	-	-	39.3%	117.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	15.6	26	20.1	35.4	35.4	20.6	15.8	35.6	39	16.3	19.3
Op. Profit Mgn % ⓘ	30.6	37.4	36.8	42.7	43.9	31.8	31.5	32.9	31.5	25	27.8
Net Profit Mgn % ⓘ	9.7	16.8	16.9	26	25.2	18.2	12.1	16.2	16	9.8	12.9
Debt to Equity ⓘ	1.2	0.6	0.3	0.1	0.8	0.9	0.8	1.4	0.8	0.8	0.3
Working Cap Days ⓘ	95	81	81	75	79	84	77	75	69	87	46
Cash Conv. Cycle ⓘ	29	24	35	28	25	34	26	40	41	42	-18

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 32.54%

Net Profit is growing at healthy rate in last 3 years 23.87%

Debt to equity has declined versus last 3 years average to 0.77

Sales growth is good in last 4 quarters at 13.77%

Return on Equity has declined versus last 3 years average to 19.30%

Latest Financials - Epigral Ltd.

	Standalone	Consolidated
TTM EPS (₹)	67.8	68
TTM Sales (₹ Cr.)	2,273	2,273
BVPS (₹.) ⓘ	401.6	401.8
Reserves (₹ Cr.) ⓘ	1,690	1,690
P/BV ⓘ	4.92	4.92
PE ⓘ	29.14	29.04

From the Market
52 Week Low / High (₹)	886.50 / 2408.35
All Time Low / High (₹)	386.35 / 2408.35
Market Cap (₹ Cr.)	8,525
Equity (₹ Cr.)	43.1
Face Value (₹)	10
Industry PE ⓘ	55.9

Management X-Ray of Epigral:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Epigral

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Epigral

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	352	398	392	598	710	611	829	1,551	2,188	1,929
Operating Expenses ⓘ	244	249	247	342	399	416	567	1,041	1,499	1,448
Manufacturing Costs	25	40	40	48	38	52	70	163	234	226
Material Costs	187	180	173	238	255	275	385	761	1,115	1,061
Employee Cost	10	12	14	16	21	33	41	52	69	81
Other Costs ⓘ	22	17	21	40	83	57	71	65	82	80
Operating Profit ⓘ	108	149	144	255	312	194	261	509	689	481
Operating Profit Margin (%)	30.6%	37.4%	36.8%	42.7%	43.9%	31.8%	31.5%	32.9%	31.5%	24.9%
Other Income ⓘ	4	2	1	4	14	9	7	8	9	10
Interest ⓘ	27	19	14	9	30	17	34	48	67	77
Depreciation ⓘ	42	44	55	55	54	44	74	86	109	124
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	42	88	75	195	242	141	161	383	523	291
Tax ⓘ	8	21	9	40	59	29	60	131	169	95
Profit After Tax	35	67	67	155	183	112	101	253	353	196
PAT Margin (%)	9.9%	16.9%	17.0%	26.0%	25.7%	18.3%	12.2%	16.3%	16.1%	10.1%
Adjusted EPS (₹)	4.9	9.5	9.4	22.0	44.4	27.0	24.3	60.8	85.0	47.1
Dividend Payout Ratio (%)	73%	0%	0%	0%	0%	0%	0%	0%	6%	11%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	220	295	362	517	493	583	684	726	1,069	1,254
Share Capital ⓘ	71	71	71	71	252	252	252	42	42	42
Reserves ⓘ	149	224	291	447	241	331	432	684	1,028	1,213
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	179	123	60	34	368	438	416	848	636	768
Long Term Debt	179	113	45	1	365	418	340	768	545	547
Short Term Debt	0	9	15	33	2	20	75	80	92	221
Trade Payables	26	27	18	33	36	47	73	88	110	165
Others Liabilities ⓘ	109	95	82	79	147	204	276	461	617	607
Total Liabilities ⓘ	534	540	522	663	1,044	1,273	1,449	2,124	2,432	2,794
Fixed Assets
Gross Block	677	408	497	498	499	688	1,424	1,475	2,320	2,406
Accumulated Depreciation	266	44	99	150	204	248	321	407	516	639
Net Fixed Assetsⓘ	411	364	398	347	295	440	1,102	1,068	1,804	1,767
CWIP ⓘ	7	69	3	79	468	691	126	589	158	483
Investmentsⓘ	17	0	29	71	0	0	0	0	21	21
Inventories	19	37	28	30	41	48	54	154	212	263
Trade Receivables	43	46	44	77	77	76	119	256	166	179
Cash Equivalents	1	1	0	5	129	0	1	25	15	7
Others Assetsⓘ	36	23	20	54	34	16	47	31	56	76
Total Assets ⓘ	534	540	522	663	1,044	1,273	1,449	2,124	2,432	2,794

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	113	123	138	225	261	165	229	284	626	398
PBT ⓘ	42	88	75	195	242	141	161	383	523	291
Adjustment ⓘ	66	64	73	61	70	56	103	130	170	196
Changes in Working Capital ⓘ	14	-11	10	7	8	-4	-6	-169	41	-38
Tax Paid ⓘ	-10	-17	-20	-38	-59	-28	-29	-60	-107	-51
Cash Flow From Investing Activity ⓘ	-18	-40	-63	-167	-217	-363	-197	-455	-437	-401
Capex	-3	-59	-35	-122	-303	-369	-197	-456	-416	-398
Net Investments	-16	18	-28	-112	82	2	0	1	-1	-3
Others ⓘ	1	0	0	68	4	4	0	0	-20	0
Cash Flow From Financing Activityⓘ	-120	-83	-76	-58	85	69	-32	195	-200	-8
Net Proceeds from Shares ⓘ	0	0	0	0	15	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	-70	0	0	350	110	-47	239	-64	17
Interest Paid ⓘ	-29	-22	-14	-9	-9	-37	-40	-48	-60	-72
Dividend Paid ⓘ	-25	0	0	0	-3	0	0	0	-10	-10
Others ⓘ	-66	9	-62	-49	-268	-4	54	4	-65	58
Net Cash Flow ⓘ	-25	0	0	0	129	-129	1	24	-11	-11

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	16.23	26.27	20.26	35.37	45.75	34.23	23.85	42.16	39.37	16.85
ROCE (%)	13.83	22.27	18.45	37.92	36.88	15.9	16.74	29.4	32.2	17.69
Asset Turnover Ratio	0.71	0.83	0.84	1.04	0.85	0.55	0.63	0.9	1.02	0.77
PAT to CFO Conversion(x)	3.23	1.84	2.06	1.45	1.43	1.47	2.27	1.12	1.77	2.03
Working Capital Days
Receivable Days	42	36	37	36	39	44	42	43	33	31
Inventory Days	19	23	27	17	18	26	22	24	29	43
Payable Days	47	54	48	39	50	55	57	39	32	47

Epigral Ltd Stock News

Epigral Ltd FAQs

What is the share price of Epigral?

Company share prices are keep on changing according to the market conditions. The closing price of Epigral on 18-Nov-2024 16:59 is ₹1,976.

What is the market cap of Epigral?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 18-Nov-2024 16:59 the market cap of Epigral stood at ₹8,524.7.

What is the P/E ratio of Epigral?

The latest P/E ratio of Epigral as of 18-Nov-2024 16:59 is 29.14.

What is the P/B ratio of Epigral?

The latest P/B ratio of Epigral as of 18-Nov-2024 16:59 is 4.92.

What is the 52-week high and low of Epigral?

The 52-week high of Epigral is ₹2,408.4 and the 52-week low is ₹886.5.

What is the TTM revenue of Epigral?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Epigral is ₹2,273 ( Cr.) .

About Epigral Ltd

Meghmani Finechem Limited (MFL) is a Public Company limited by shares domiciled in India, incorporated under the provisions of Companies Act, 1956. The registered office of the company is located at GIDC Industrial Estate, Dahej, Tal. Vagara, Dist. Bharuch, Gujarat.

It is an ISO 9001 and ISO 14001-certified company founded in 2007 and recognised as one of the leading producers of chlor alkali and its Derivatives with backward and forward integration facilities. The Company meets the global essential chemicals demand with responsible care and with large-scale growth, while committing to quality and environment integrity.

MFL works out of an advanced automated production facility, which is equipped to address international standards in the manufacture of Caustic Soda, Caustic Potash, Chlorine, Hydrogen, Chloromethanes and Hydrogen Peroxide. The Company aims to service domestic as well as export markets, contributing towards the ‘Make in India’ initiative.

Business area of the company

The Company is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products.